NASDAQ:PDLI - PDL BioPharma Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$2.54 -0.01 (-0.39 %)
(As of 07/22/2018 10:11 AM ET)
Previous Close$2.54
Today's Range$2.50 - $2.56
52-Week Range$2.15 - $3.55
Volume666,744 shs
Average Volume1.37 million shs
Market Capitalization$382.63 million
P/E Ratio3.91
Dividend YieldN/A
Beta0.31
PDL BioPharma logoPDL BioPharma, Inc. acquires and manages companies, products, royalty agreements, and debt facilities in the biotechnology, pharmaceutical, and medical device industries in the United States, Europe, and internationally. The company operates in three segments: Income Generating Assets, Pharmaceutical, and Medical Devices. The Income Generating Assets segment consists of notes and other long-term receivables; royalty rights and hybrid notes/royalty receivables; equity investments in healthcare companies; and royalties from issued patents covering the humanization of antibodies, including Avastin, Herceptin, Xolair, Lucentis, Perjeta, Kadcyla, and Tysabri. The Pharmaceutical segment manufactures, markets, and sells prescription medicine products for the treatment of hypertension to wholesalers under the Tekturna and Tekturna HCT names in the United States, as well as under the Rasilez and Rasilez HCT names internationally. The Medical Devices segment manufactures and sells LENSAR laser systems for anterior capsulotomy, lens fragmentation, corneal and arcuate incisions to ophthalmic ambulatory surgical centers, specialty ophthalmic hospitals, and multi-specialty hospitals through a direct sales force. The company was formerly known as Protein Design Labs, Inc. and changed its name to PDL BioPharma, Inc. in 2006. PDL BioPharma, Inc. was founded in 1986 and is headquartered in Incline Village, Nevada.

Receive PDLI News and Ratings via Email

Sign-up to receive the latest news and ratings for PDLI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:PDLI
CUSIP69329Y10
Phone775-832-8500

Debt

Debt-to-Equity Ratio0.14
Current Ratio10.03
Quick Ratio9.75

Price-To-Earnings

Trailing P/E Ratio3.91
Forward P/E Ratio11.55
P/E GrowthN/A

Sales & Book Value

Annual Sales$320.06 million
Price / Sales1.20
Cash Flow$0.8789 per share
Price / Cash2.89
Book Value$5.48 per share
Price / Book0.46

Profitability

EPS (Most Recent Fiscal Year)$0.63
Net Income$110.74 million
Net Margins33.57%
Return on Equity11.76%
Return on Assets8.04%

Miscellaneous

Employees87
Outstanding Shares150,640,000
Market Cap$382.63

PDL BioPharma (NASDAQ:PDLI) Frequently Asked Questions

What is PDL BioPharma's stock symbol?

PDL BioPharma trades on the NASDAQ under the ticker symbol "PDLI."

How will PDL BioPharma's stock buyback program work?

PDL BioPharma declared that its Board of Directors has approved a share buyback plan on Monday, September 25th 2017, which authorizes the company to buyback $25,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization authorizes the company to repurchase shares of its stock through open market purchases. Shares buyback plans are typically a sign that the company's board believes its stock is undervalued.

How were PDL BioPharma's earnings last quarter?

PDL BioPharma Inc (NASDAQ:PDLI) issued its quarterly earnings data on Wednesday, May, 9th. The biotechnology company reported $0.08 earnings per share for the quarter, topping analysts' consensus estimates of $0.06 by $0.02. The biotechnology company had revenue of $38.52 million for the quarter. PDL BioPharma had a return on equity of 11.76% and a net margin of 33.57%. View PDL BioPharma's Earnings History.

When is PDL BioPharma's next earnings date?

PDL BioPharma is scheduled to release their next quarterly earnings announcement on Wednesday, August, 1st 2018. View Earnings Estimates for PDL BioPharma.

What price target have analysts set for PDLI?

2 brokerages have issued 12-month target prices for PDL BioPharma's stock. Their predictions range from $2.50 to $4.00. On average, they anticipate PDL BioPharma's stock price to reach $3.25 in the next year. This suggests a possible upside of 28.0% from the stock's current price. View Analyst Ratings for PDL BioPharma.

What is the consensus analysts' recommendation for PDL BioPharma?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PDL BioPharma in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."

Who are some of PDL BioPharma's key competitors?

Who are PDL BioPharma's key executives?

PDL BioPharma's management team includes the folowing people:
  • Mr. John Peter McLaughlin J.D., CEO & Director (Age 66)
  • Mr. Peter S. Garcia, VP & CFO (Age 56)
  • Mr. Steffen Pietzke, VP of Fin. & Chief Accounting Officer (Age 46)
  • Mr. Christopher L. Stone J.D., VP, Gen. Counsel & Sec. (Age 54)
  • Mr. Dominique P. Monnet, Pres (Age 57)

Has PDL BioPharma been receiving favorable news coverage?

News coverage about PDLI stock has been trending somewhat positive recently, according to Accern Sentiment Analysis. The research group scores the sentiment of press coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. PDL BioPharma earned a daily sentiment score of 0.07 on Accern's scale. They also gave headlines about the biotechnology company an impact score of 47.13 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next several days.

Who are PDL BioPharma's major shareholders?

PDL BioPharma's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Bank of Montreal Can (0.40%) and Hartford Investment Management Co. (0.07%). View Institutional Ownership Trends for PDL BioPharma.

Which major investors are selling PDL BioPharma stock?

PDLI stock was sold by a variety of institutional investors in the last quarter, including Bank of Montreal Can. View Insider Buying and Selling for PDL BioPharma.

Which major investors are buying PDL BioPharma stock?

PDLI stock was bought by a variety of institutional investors in the last quarter, including Hartford Investment Management Co.. View Insider Buying and Selling for PDL BioPharma.

How do I buy shares of PDL BioPharma?

Shares of PDLI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is PDL BioPharma's stock price today?

One share of PDLI stock can currently be purchased for approximately $2.54.

How big of a company is PDL BioPharma?

PDL BioPharma has a market capitalization of $382.63 million and generates $320.06 million in revenue each year. The biotechnology company earns $110.74 million in net income (profit) each year or $0.63 on an earnings per share basis. PDL BioPharma employs 87 workers across the globe.

How can I contact PDL BioPharma?

PDL BioPharma's mailing address is 932 SOUTHWOOD BLVD, INCLINE VILLAGE NV, 89451. The biotechnology company can be reached via phone at 775-832-8500 or via email at [email protected]


MarketBeat Community Rating for PDL BioPharma (NASDAQ PDLI)

Community Ranking:  1.4 out of 5 (star)
Outperform Votes:  112 (Vote Outperform)
Underperform Votes:  279 (Vote Underperform)
Total Votes:  391
MarketBeat's community ratings are surveys of what our community members think about PDL BioPharma and other stocks. Vote "Outperform" if you believe PDLI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PDLI will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.